Supreme Court rules employers must be more accommodating of religious observance

3:53TheU.S.SupremeCourtisseenonJune23,2023inWashington,D.C.KevinDietsch/GettyImagesAunanimousSupreme ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri




comprehensive

author：fashion    Page View：98
Alastair Grant/AP

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

advertisement

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Supreme Court rules employers must be more accommodating of religious observance
Next article： Dobbs anniversary: the lost opportunity of abortion as health care